Business Context and Reporting Period
This Form 8-K Current Report from Marchex, Inc. covers events occurring on September 28, 2023. The filing primarily details the outcomes of the company's 2023 Annual Meeting of Stockholders and the subsequent entry into material definitive agreements regarding director and executive compensation.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on corporate governance and compensation arrangements.
- Director Cash Compensation: $7,500 per quarter for independent directors.
- Director Equity Grants: 15,000 restricted shares (purchase price $0.01) and 20,000 options (exercise price $1.45) per director.
- Executive Equity Grants: 350,000 options to CEO Edwin A. Miller and 300,000 options to CRO Troy Hartless (exercise price $1.45).
Material Changes and Corporate Actions
Following the re-election of the Board of Directors, the company implemented new compensation packages under the 2021 Stock Incentive Plan:
- Director Vesting: 50% of restricted stock and options vest on the first and second annual anniversaries, respectively, with full acceleration upon a Change in Control.
- Executive Vesting: Options vest over four years (25% on the first anniversary, then quarterly increments of 6.25%), with accelerated vesting provisions for certain events.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding business operations or financial outlook. The document serves strictly to disclose the results of the stockholder vote and the specific terms of the compensation agreements.
Investor Verification Checklist
- Verify the total number of directors to calculate the aggregate equity dilution from the 15,000 restricted shares and 20,000 options granted per director.
- Confirm the total outstanding share count to assess the impact of the 650,000 new executive options granted to the CEO and CRO.
- Review the 2021 Stock Incentive Plan to ensure sufficient shares remain available for these grants.
- Note the stock price of $1.45 on the grant date as the basis for the exercise price of all new options.